AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aptorum Group and DiamiR Biosciences Announce Two Abstracts Accepted for Presentation at CTAD 2025 Conference
ByAinvest
Wednesday, Nov 19, 2025 8:02 am ET1min read
DiamiR Biosciences and Aptorum Group announced two poster presentations at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference. The presentations highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration. The studies were funded by the Small Business Innovation Research Grant from the National Institute on Aging. The merger between Aptorum Group and DiamiR Biosciences is expected to close in the first quarter of 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet